OPERATIONS

We operate in multiple locations to ensure high service delivery and innovation. Our facilities in Greece, Lesotho and Southern Africa allow us great reach through the African continent, Europe and into Asia. We have access to 11,000 pharmacies, 35,000 doctors and 100 wholesalers in over 21 countries. We seek to improve the lives of as many people as possible, and are achieving this through a diversified location system.

Cannsun Medhel cannabis pharmaceutical
Cannsun Medhel

Greece

Athens

  • 70,500 square foot EUGMP certified pharmaceutical manufacturing facility located in Athens, Greece. 
  • More than 75 SKU’s by year end 2020
  • Access to 11,000 pharmacies, 35,000 doctors & 100 wholesalers in Greece and sales to over 21 countries in Europe, Asia & Africa
  • Obtaining Schedule I & III License by Q1 2021 that will enable us to immediately batch release & distribute THC flower/concentrate and other narcotic classified products.
  • Large sales force in place with sales and distribution across Europe, Africa and Asia.

Thessaloniki

  • Cannabis cultivation license awarded December 2019, 12.6 hectare site.
  • Phase 1: 3.0 hectare Greenhouse construction start Q1 2021
  • Phase 2: Additional 2.0 hectares of greenhouse to be built 2022

South Africa

Cape Town

  • Africa’s largest medical cannabis licence for cultivation was awarded to Cannsun in January 2020 for our 23 hectare facility in Atlantis, Cape Town,
  • Phase 1: Complete with a 2,500 m2 facility under flower, first harvest expected end of July 2020
  • Phase 2: an additional 3.0 hectares of cultivation & extraction, construction to commence Q4 2020
  • BBBEE complaint, increasing participation of South African labor in economic activities
Cannsun Medhel cannabis pharmaceutical

Lesotho

  • Alpine: 1 cultivation license awarded, 1.5 hectare Phase 1 development, construction currently underway
  • BBBEE complaint, increasing participation of South African labor in economic activities
Thailand Cannsun Medhel

ASEAN

  • Thailand: Cannsun Medhel Thailand has agreement to acquire an existing GMP extraction facility for botanicals, including hemp (CBD)
  • Cannsun Thailand has submitted application for manufacturing Cosmetics and Adaptogens including CBD, expect approval July 2020
  • MOU with Mahasarakham University and Natural Medicine hospital to develop botanical formulations with CBD and THC
  • Malaysia: distribution of Cannsun Medhel products in Malaysia with application process in place to potentially distribute pharmaceutical products in late 2020
Scroll to Top